Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2023 | $30.00 → $3.00 | Buy → Hold | Canaccord Genuity |
| 2/18/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 11/30/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $20.00 → $35.00 | Buy | Aegis Capital |
| 7/29/2021 | $27.00 → $30.00 | Buy | Canaccord Genuity |
Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously
Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously
Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Semi-annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranking them by total ma
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
NT 10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026. Semi-annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranking them by total ma
NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market. Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned
Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. Oramed retains a $27 million note and a $12 million convertible note with Scilex, convert
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last yearCompleted
SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)